Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India · Delayed Price · Currency is INR 1,119.10
+40.85 (3.79%)
Last updated: Sep 7, 2026, 9:35 AM IST
Symbiotec Pharmalab Revenue
In the fiscal year ending March 31, 2026, Symbiotec Pharmalab had annual revenue of 8.69B INR with 15.65% growth. Symbiotec Pharmalab had revenue of 2.03B in the quarter ending June 30, 2025.
Revenue
8.69B
Revenue Growth
+15.65%
P/S Ratio
7.97
Revenue / Employee
4.54M
Employees
1,752
Market Cap
69.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.69B | 1.18B | 15.65% |
| Mar 31, 2025 | 7.52B | 353.07M | 4.93% |
| Mar 31, 2024 | 7.16B | 1.50B | 26.43% |
| Mar 31, 2023 | 5.67B | -1.15B | -16.91% |
| Mar 31, 2022 | 6.82B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 25.24B |
| Neuland Laboratories | 23.72B |
| Shilpa Medicare | 16.83B |
| Bajaj HealthCare | 6.28B |
| NGL Fine-Chem | 5.36B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
| Influx Healthtech | 1.47B |